Hemostemix Inc HEM

TSXV · Kanada · Gesundheitstechnologie

CAD 0,06000,00 (0,00 %)

Markt geschlossen· 01.10.2026, 15:10 UTC· CAD · Daten können verzögert sein

Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.

Hemostemix Inc HEM

TSXV · Kanada · Gesundheitstechnologie

CAD 0,06000,00 (0,00 %)

Markt geschlossen· 01.10.2026, 15:10 UTC· CAD · Daten können verzögert sein

Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.

-14,29 % · 6MVollbild-Chart

Eröffnung CAD 0,0600Hoch CAD 0,0600Tief CAD 0,0600Schluss CAD 0,0600Volumen 5.00K

1. Okt. 2026

Charts by TradingView Lightweight Charts

Kennzahlen

Vortagesschluss: CAD 0,0600
Tagesspanne: CAD 0,0600 – CAD 0,0600
52-Wochen-Spanne: CAD 0,0400 – CAD 0,1250
Volumen: 5,00K
Marktkapitalisierung: CAD 12,69M
Nächster Quartalsbericht: 2026-11-27
Ø Volumen (1J): 59,13K

Wertentwicklung

1 Woche

-7,69 %

1 Monat

-14,29 %

3 Monate

+9,09 %

6 Monate

-14,29 %

Seit Jahresbeginn

-33,33 %

1 Jahr

-40,00 %

Gesamtrendite inklusive Dividenden.

Unternehmensprofil

Sektor: Gesundheitstechnologie
Branche: Biotechnology
Land: Kanada
Börse: TSXV
Ausstehende Aktien: 211,44M
ISIN: CA4236943060
Beta: 0,74

Technischer Blick

Unter den Durchschnitten

Wo der Kurs im Verhältnis zu seinen 50- und 200-Tage-Durchschnitten steht.

Bewertung & Analyse

Makkler Fair Value, Finanzgesundheit, Analystenmeinung, Vergleichsunternehmen und MakklerAI.

Nachrichten

Yahoo Finance28. Sept. 2026

Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit

Calgary, Alberta--(Newsfile Corp. - September 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that it is presenting at the Centurion One Capital 4th Annual Bahamas Summit at Rosewood Baha Mar in Nassau, The Bahamas, October 19 to October 21, 2026.The invitation-only summit brings together company executives, institutional investors and family offices for company presentations, panel discussions and one-on-one meetings....

Yahoo Finance23. Sept. 2026

Hemostemix Non Brokered Private Placement

Calgary, Alberta--(Newsfile Corp. - September 23, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is filing a Form 4B to obtain price protection for the closing of the third tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026, to raise $1,000,000. Each Unit consists of one common share in the capital of the Company (a "Common Share") and...

Yahoo Finance20. Aug. 2026

Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA

Leading cognitive-disorders specialist, Dr. William Shankle, will discuss vascular cognitive impairment, vascular dementia and the proposed clinical trial of VesCell™ (ACP-01) today at 12:00 EST, at https://us06web.zoom.us/webinar/register/WN_nJ8ViLkRSeiU_NXMYJ-jbwCalgary, Alberta--(Newsfile Corp. - August 20, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce > 130 participants have enrolled to hear Dr. William R. Shankle, MS,..